Menest Related Published Studies
Well-designed clinical trials related to Menest (Esterified Estrogens)
Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study. [2011.01]
Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. [2007.03]
Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women. [2005.07]
Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women. [2005.06]
Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women. [2004.05]
Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. [2003.06]
Esterified estrogens combined with methyltestosterone improve emotional well-being in postmenopausal women with chest pain and normal coronary angiograms. [2001.07]
Preliminary observations on differing psychological effects of conjugated and esterified estrogen treatments. [2001.03]
Esterified estrogen therapy in postmenopausal women. Relationships of bone marker changes and plasma estradiol to BMD changes: a two-year study. [2000.11]
Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women. [2000.09]
Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. [1997.12.08]
[Comparison of the relative bioavailability and pharmacokinetics of estrone after oral administration of esterified estrogens in a tablet formulation and an aqueous suspension] [1997.02]
A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. [1993.12]
Well-designed clinical trials possibly related to Menest (Esterified Estrogens)
Follicular, oocyte and embryo features related to metabolic status in primiparous lactating does fed with high-fibre rearing diets. [2010.10]
Low and ultra low-dose estrogen therapy for climacteric symptom control--preliminary report. [2006.07]
Differential effects of oral and transdermal estradiol treatment on circulating estradiol fatty acid ester concentrations in postmenopausal women. [2003.02]
Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. [2002.04]
Neuropsychological effects of methyltestosterone in women using menopausal hormone replacement. [2001.09]
Effect of low-dose estrogen on hemodynamic response to stress. [2001.02]
A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. [1999.12]
Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. [1999.06]
Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. [1998.10]
Enterohepatic cycling and pharmacokinetics of oestradiol in postmenopausal women. [1998.08]
Ovarian hormones and vaginal blood flow: using laser Doppler velocimetry to measure effects in a clinical trial of post-menopausal women. [1998.05]
Vasodilator effects of estrogen are not diminished by androgen in postmenopausal women. [1997.12]
Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. [1996.01]
Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. [1995.04]
Other research related to Menest (Esterified Estrogens)
Safety and efficacy of low-dose esterified estrogens and methyltestosterone,
alone or combined, for the treatment of hot flashes in menopausal women: a
randomized, double-blind, placebo-controlled study. [2011]
Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study. [2010.09.16]
Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women. [2006.12]
Esterified estrogens combined with methyltestosterone raise intraocular pressure in postmenopausal women. [2006.09]
The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women. [2006.08]
Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. [2006.02.27]
Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. [2004.10.06]
Estratest and Estratest HS (esterified estrogens and methyltestosterone) therapy: a summary of safety surveillance data, January 1989 to August 2002. [2003.12]
Low-dosage esterified estrogens opposed by progestin at 6-month intervals. [2001.08]
[Equine estrogens vs. esterified estrogens in the climacteric and menopause. The controversy arrives in Mexico] [2001.05]
Evaluation of a formulary switch from conjugated to esterified estrogens in a managed care setting. [2000.09]
Safety surveillance of esterified estrogens-methyltestosterone (Estratest and Estratest HS) replacement therapy in the United States. [1997.09]
Esterified estrogens with and without methyltestosterone decrease arterial LDL metabolism in cynomolgus monkeys. [1996.12]
Other possibly related research studies
Drugs in development for Parkinson's disease: an update. [2006.01]
Drugs in development for Parkinson's disease. [2004.07]
Low-dose estrogen therapy for menopausal women: a review of efficacy and safety. [2003.10]
Effects of feeding blends of grains naturally contaminated with Fusarium mycotoxins on production and metabolism in broilers. [2002.07]
Altered distribution of lipid-soluble antioxidant vitamins in juvenile sturgeon exposed to waterborne ethynylestradiol. [2001.10]
Safety of estrogen/androgen regimens. [2001.03]
HRT dosing regimens: continuous versus cyclic-pros and cons. [2001.01]
[Basic principles of hormone replacement therapy in the postmenopause] [2000.10]
Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995. [2000.09]
Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995. [2000.08]
Dietary soy-derived isoflavone phytoestrogens. Could they have a role in coronary heart disease prevention? [2000.07.01]
Effects of reserpine on expression of the LDL receptor in liver and on plasma and tissue lipids, low density lipoprotein and fibrinogen in rabbits in vivo. [2000.04]
Moderation of the daily dose of HRT: prevention of osteoporosis. [1999.11]
Lipid transfer reactions and lipid composition of low-density lipoprotein particles in postmenopausal women receiving estrogen. [1999.10]
Liver function in postmenopausal women on estrogen-androgen hormone replacement therapy: a meta-analysis of eight clinical trials. [1999.09]
Safety evaluation of phytosterol esters. Part 1. Assessment of oestrogenicity using a combination of in vivo and in vitro assays. [1999.01]
Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. [1998.07]
Role of the ovary in the adrenal androgen excess of hyperandrogenic women. [1998.05]
Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. [1997.08]
Effects of contraceptive estrogen and progestin on the atherogenic potential of plasma LDLs in cynomolgus monkeys. [1997.07]
[Effects of estrogenic hormones on blood lipids] [1975]
Influence of estrogen plus testosterone supplementation on breast cancer. [2009.01.12]
Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer. [2009.01]
|
